Graham Warren to United States
This is a "connection" page, showing publications Graham Warren has written about United States.
Connection Strength
0.662
-
Tobacco and E-cigarette use among cancer survivors in the United States. PLoS One. 2019; 14(12):e0226110.
Score: 0.071
-
Considering Systemic Barriers to Treating Tobacco Use in Clinical Settings in the United States. Nicotine Tob Res. 2019 10 26; 21(11):1453-1461.
Score: 0.070
-
Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer. JAMA Netw Open. 2019 04 05; 2(4):e191703.
Score: 0.067
-
American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products. J Oncol Pract. 2017 01; 13(1):58-60.
Score: 0.057
-
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 10; 33(8):952-63.
Score: 0.050
-
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res. 2015 Feb 01; 21(3):514-25.
Score: 0.050
-
The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer. 2014 Jul 01; 120(13):1914-6.
Score: 0.048
-
Accuracy of self-reported tobacco use in newly diagnosed cancer patients. Cancer Causes Control. 2013 Jun; 24(6):1223-30.
Score: 0.044
-
Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book. 2013; 359-64.
Score: 0.044
-
The Impact of the COVID-19 Pandemic on Tobacco Treatment Program Implementation at National Cancer Institute-Designated Cancer Centers. Nicotine Tob Res. 2023 01 05; 25(2):345-349.
Score: 0.022
-
Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res. 2022 Nov 14; 28(22):4861-4870.
Score: 0.022
-
The first 20 months of the COVID-19 pandemic: Mortality, intubation and ICU rates among 104,590 patients hospitalized at 21 United States health systems. PLoS One. 2022; 17(9):e0274571.
Score: 0.021
-
Pragmatic Application of the RE-AIM Framework to Evaluate the Implementation of Tobacco Cessation Programs Within NCI-Designated Cancer Centers. Front Public Health. 2020; 8:221.
Score: 0.018
-
Development and Validation of Nomograms for Predicting Delayed Postoperative Radiotherapy Initiation in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2020 05 01; 146(5):455-464.
Score: 0.018
-
Subsite variation in survival of oropharyngeal squamous cell carcinomas 2004 to 2011. Laryngoscope. 2017 05; 127(5):1087-1092.
Score: 0.014
-
Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop. Oncologist. 2014 Jan; 19(1):21-31.
Score: 0.012
-
Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck. 2014 May; 36(5):694-701.
Score: 0.012
-
Prognostic implications of signet ring cell histology in esophageal adenocarcinoma. Cancer. 2013 Sep 01; 119(17):3156-61.
Score: 0.011
-
Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res. 2013 Apr 15; 19(8):1941-8.
Score: 0.011